CA2982612A1 - Use of cd24 for lowering low-density lipoprotein cholesterol levels - Google Patents

Use of cd24 for lowering low-density lipoprotein cholesterol levels Download PDF

Info

Publication number
CA2982612A1
CA2982612A1 CA2982612A CA2982612A CA2982612A1 CA 2982612 A1 CA2982612 A1 CA 2982612A1 CA 2982612 A CA2982612 A CA 2982612A CA 2982612 A CA2982612 A CA 2982612A CA 2982612 A1 CA2982612 A1 CA 2982612A1
Authority
CA
Canada
Prior art keywords
protein
subject
ldl
mins
cd24fc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2982612A
Other languages
English (en)
French (fr)
Inventor
Yang Liu
Pan Zheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncoimmune Inc
Original Assignee
Oncoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoimmune Inc filed Critical Oncoimmune Inc
Publication of CA2982612A1 publication Critical patent/CA2982612A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
CA2982612A 2015-05-07 2016-05-06 Use of cd24 for lowering low-density lipoprotein cholesterol levels Abandoned CA2982612A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562158157P 2015-05-07 2015-05-07
US62/158,157 2015-05-07
PCT/US2016/031109 WO2016179456A1 (en) 2015-05-07 2016-05-06 Use of cd24 for lowering low-density lipoprotein cholesterol levels

Publications (1)

Publication Number Publication Date
CA2982612A1 true CA2982612A1 (en) 2016-11-10

Family

ID=57218627

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2982612A Abandoned CA2982612A1 (en) 2015-05-07 2016-05-06 Use of cd24 for lowering low-density lipoprotein cholesterol levels

Country Status (18)

Country Link
US (2) US10369197B2 (cg-RX-API-DMAC7.html)
EP (1) EP3292144B1 (cg-RX-API-DMAC7.html)
JP (1) JP6751756B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170141216A (cg-RX-API-DMAC7.html)
CN (1) CN107531772B (cg-RX-API-DMAC7.html)
AU (1) AU2016258084B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017022394A2 (cg-RX-API-DMAC7.html)
CA (1) CA2982612A1 (cg-RX-API-DMAC7.html)
EA (1) EA038520B1 (cg-RX-API-DMAC7.html)
ES (1) ES2829235T3 (cg-RX-API-DMAC7.html)
HK (1) HK1249521A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20201651T1 (cg-RX-API-DMAC7.html)
HU (1) HUE051866T2 (cg-RX-API-DMAC7.html)
IL (1) IL255086B (cg-RX-API-DMAC7.html)
MX (1) MX385941B (cg-RX-API-DMAC7.html)
PT (1) PT3292144T (cg-RX-API-DMAC7.html)
WO (1) WO2016179456A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201706846B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20201651T1 (hr) * 2015-05-07 2020-12-25 Oncoimmune, Inc. Uporaba cd24 za snižavanje razina lipoproteina niske gustoće kolesterola
JP2020510020A (ja) * 2017-03-07 2020-04-02 オンコイミューン， インコーポレイテッド 全身性エリテマトーデスを治療するために可溶性ｃｄ２４を使用する方法
WO2019113123A1 (en) * 2017-12-04 2019-06-13 Precithera, Inc. TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING
CN112543643A (zh) * 2018-03-05 2021-03-23 肿瘤免疫股份有限公司 使用可溶性cd24用于治疗获得性免疫缺陷综合征（hiv/aids）的方法
MA52811A (fr) * 2018-06-04 2022-03-16 Oncoimmune Inc Procédés d'utilisation de cd24 pour la prévention et le traitement d'une rechute de la leucémie
WO2020084034A1 (en) 2018-10-26 2020-04-30 F. Hoffmann-La Roche Ag Multispecific antibody screening method using recombinase mediated cassette exchange
CA3128503A1 (en) * 2019-02-06 2020-08-13 Oncoimmune, Inc. Targeting cd24-siglec interactions for treating subjects with prediabetes or diabetes
US20220000973A1 (en) * 2019-02-06 2022-01-06 Oncolmmune, Inc. Targeting CD24-Siglec Interactions for the Treatment and Prevention of Nonalcoholic Steatohepatitis
WO2021160170A1 (en) * 2020-02-10 2021-08-19 Oncoimmune, Inc. Methods of use of soluble cd24 for treating sars-cov-2 infection
EP4103217A4 (en) * 2020-02-10 2024-03-13 Oncoimmune Inc. METHOD OF USING SOLUBLE CD24 TO TREAT VIRAL PNEUMONIA

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544566B1 (en) * 1999-04-23 2003-04-08 Protein Technologies International, Inc. Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol
AU2001259792B2 (en) * 2000-03-29 2005-12-22 The Ohio State University Research Foundation Methods of blocking tissue destruction by autoreactive T cells
CN1981772A (zh) * 2000-05-13 2007-06-20 阿彻-丹尼尔斯-米德兰公司 降低低密度脂蛋白胆固醇浓度的组合物和方法
WO2009086284A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Cd24 as a brain tumor stem cell marker and a diagnostic and therapeutic target in primary neaural and glial tumors of the brain
US8163281B2 (en) * 2009-03-04 2012-04-24 The Regents Of The University Of Michigan Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis
US8354520B2 (en) * 2009-12-10 2013-01-15 Kaohsiung Medical University Composition and method for treating atherosclerosis, method for determining if a subject has atherosclerosis and method of screening an anti-atherosclerotic drug
US20130231464A1 (en) * 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
US8808697B2 (en) * 2010-04-28 2014-08-19 Oncoimmune, Inc. Methods of use of soluble CD24 for therapy of rheumatoid arthritis
AU2012267489B2 (en) * 2011-06-10 2017-03-16 The Trustees Of The University Of Pennsylvania System and method of cytomic vascular health profiling
HRP20201651T1 (hr) * 2015-05-07 2020-12-25 Oncoimmune, Inc. Uporaba cd24 za snižavanje razina lipoproteina niske gustoće kolesterola

Also Published As

Publication number Publication date
AU2016258084B2 (en) 2020-01-30
US11026995B2 (en) 2021-06-08
WO2016179456A1 (en) 2016-11-10
ZA201706846B (en) 2018-12-19
EP3292144A4 (en) 2018-11-14
US10369197B2 (en) 2019-08-06
HRP20201651T1 (hr) 2020-12-25
IL255086B (en) 2021-08-31
CN107531772A (zh) 2018-01-02
KR20170141216A (ko) 2017-12-22
HUE051866T2 (hu) 2021-03-29
HK1249521A1 (zh) 2018-11-02
EP3292144B1 (en) 2020-08-26
EP3292144A1 (en) 2018-03-14
US20180110828A1 (en) 2018-04-26
BR112017022394A2 (pt) 2018-07-17
JP6751756B2 (ja) 2020-09-09
MX2017014095A (es) 2018-03-16
ES2829235T3 (es) 2021-05-31
AU2016258084A1 (en) 2017-11-02
CN107531772B (zh) 2021-09-21
EA038520B1 (ru) 2021-09-09
US20190307841A1 (en) 2019-10-10
MX385941B (es) 2025-03-18
IL255086A0 (en) 2017-12-31
EA201792418A1 (ru) 2018-02-28
PT3292144T (pt) 2020-11-05
JP2018515605A (ja) 2018-06-14

Similar Documents

Publication Publication Date Title
US11026995B2 (en) Use of CD24 for lowering low-density lipoprotein cholesterol levels
US10793617B2 (en) Methods of use of soluble CD24 for therapy of rheumatoid arthritis
JP2019151655A (ja) 関節リウマチの治療のための可溶性ｃｄ２４の使用方法
US20210162006A1 (en) Use of CD24 Proteins for Treating Leptin-Deficient Conditions
KR20200034957A (ko) 신경 보호 및 재수초화를 위한 가용성 cd24의 사용 방법
KR20190126801A (ko) 전신 홍반성 루푸스를 치료하기 위한 가용성 cd24의 사용 방법
CA3128503A1 (en) Targeting cd24-siglec interactions for treating subjects with prediabetes or diabetes
HK40002090A (en) Use of cd24 proteins for treating leptin-deficient conditions
HK40017772A (en) Methods of use of soluble cd24 for treating systemic lupus erythematosus

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210421

FZDE Discontinued

Effective date: 20230912